Stereoselective synthesis of highly functionalised P-stereogenic nucleosides via palladium-catalysed P-C cross-coupling reactions

Tetrahedron Letters

Volumn 49, Issue 49, 2008, Pages 6984-6987

  Whittaker, Benjamin ^a   Ruiz, Manuel de Lera ^a   Hayes, Christopher J ^a  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HALIDE; NUCLEOSIDE DERIVATIVE; OLIGONUCLEOTIDE; PALLADIUM; PHOSPHONIC ACID DERIVATIVE; VINYL DERIVATIVE;

ARTICLE; CATALYSIS; CATALYST; CHEMICAL STRUCTURE; CHROMATOGRAPHY; CROSS COUPLING REACTION; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PROTON NUCLEAR MAGNETIC RESONANCE; STEREOCHEMISTRY; STEREOISOMERISM; SYNTHESIS;

EID: 54049150278     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2008.09.102     Document Type: Article

References (45)

1. Szymkowski D.E. Drug Discovery Today 1 (1996) 415
2. Englisch U., and Gauss D.H. Angew. Chem., Int. Ed. 30 (1991) 613
3. The first antisense oligonucleotide therapeutic (Vitravene™), based upon a phosphorothioate internucleotide linkage, was approved by the FDA in August 1998 for treatment of CMV retinitis.
4. Hannon G. Nature 418 (2002) 244
5. Fire A., Xu S., Montgomery M., Kostas S., Driver S., and Mello C. Nature 391 (1998) 806
6. Rogers F.A., Lloyd J.A., and Glazer P.M. Curr. Med. Chem. Anticancer Agents 5 (2005) 319
7. Rogers F.A., Manoharan M., Rabinovitch P., Ward D.C., and Glazer P.M. Nucl. Acids Res. 32 (2004) 6595
8. Knauert M.P., and Glazer P.M. Hum. Mol. Genet. 10 (2001) 2243
9. Praseuth D., Guieysse A.L., and Hélène C. Biochim. Biophys. Acta 1489 (1999) 181
10. Uhlmann E., and Peyman A. Chem. Rev. 90 (1990) 543
11. Uhlmann E., Peyman A., Breipohl G., and Will D.W. Angew. Chem., Int. Ed. 37 (1998) 2797
12. Abbas S., Bertram R.D., and Hayes C.J. Org. Lett. 3 (2001) 3365
13. Abbas S., and Hayes C.J. Tetrahedron Lett. 41 (2000) 4513
14. Abbas S., and Hayes C.J. Synlett (1999) 1124
15. Garcia P.L., Bradley G., Hayes C.J., Krintel S., Soultanas P., and Janscak P. Nucl. Acids Res. 32 (2004) 3771
16. Bertram R.D., Hayes C.J., and Soultanas P. Biochemistry 41 (2002) 7725
17. Doddridge Z.A., Bertram R.D., Hayes C.J., and Soultanas P. Biochemistry 42 (2003) 3239
18. Hirao T., Masunaga T., Yamada N., Ohshiro Y., and Agawa T. Bull. Chem. Soc. Jpn. 55 (1982) 909
19. Micklefield J., and Fettes K.J. Tetrahedron 54 (1998) 2129
20. Fettes K.J., Howard N., Hickman D.T., Adah S.A., Player M.R., Torrence P.F., and Micklefield J. Chem. Commun. (2000) 765
21. Blättler M.O., Wenz C., Pingoud A., and Benner S.A. J. Am. Chem. Soc. 120 (1998) 2674
22. Richert C., Roughton A.L., and Benner S.A. J. Am. Chem. Soc. 118 (1996) 4518
23. Roughton A.L., Portmann S., Benner S.A., and Egli M. J. Am. Chem. Soc. 117 (1995) 7249
24. Baeschlin D.K., Hyrup B., Benner S.A., and Richert C. J. Org. Chem. 61 (1996) 7620
25. Worthington R.J., O'Rourke A.P., Morral J., Tan T.H.S., and Micklefield J. Org. Biomol. Chem. 5 (2007) 249
26. Tan T.H.S., Worthington R.J., O'Rourke A.P., Morral J., Pritchard R.G., and Micklefield J. Org. Biomol. Chem. 5 (2007) 239
27. Kuman V., Pallan P.S., Ganesh M., and Ganesh K.N. Org. Lett. 3 (2001) 1269
28. Barawkar D.A., Kwok Y., Bruice T.W., and Bruice T.C. J. Am. Chem. Soc. 122 (2000) 5244
29. Thiviyanathan V., Vyazovkina K.V., Gozansky E.K., Bichenchova E., Abramova T.V., Luxon B.A., Lebedev A.V., and Gorenstein D.G. Biochemistry 41 (2002) 827
30. Smith S.A., and McLaughlin L.W. Biochemistry 36 (1997) 6046
31. Johansson T., and Stawinski J. Bioorg. Med. Chem. Lett. 9 (2001) 2315
32. Seela F., and Kretschmer U. J. Org. Chem. 56 (1991) 3861
33. Xu Y., Wei H., Zhang J., and Huang G. Tetrahedron Lett. 30 (1989) 949
34. Zhang J., Xu Y., Huang G., and Guo H. Tetrahedron Lett. 29 (1988) 1955
35. Xu Y., and Zhang J. J. Chem. Soc., Chem. Commun. (1986) 1606
36. Al-Masum M., Kumaraswamy G., and Livinghouse T. J. Org. Chem. 65 (2000) 4776
37. Oshiki T., and Imamoto T. J. Am. Chem. Soc. 114 (1992) 3975
38. For the synthesis of H-phosphonates, including the o-nitrobenzyl-substituted derivative 8d, using this method see Ref. 5b.
39. Wang J.-C., and Just G. J. Org. Chem. 64 (1999) 8090
40. Iyer R.P., Egan W., Regan J.B., and Beaucage S.L. J. Am. Chem. Soc. 112 (1990) 1253
41. It is important to note that no inversion occurs during this process, and the apparent change in absolute configuration is simply due to the order of the group priorities used in the CIP rules.
42. Similar chromatographic mobility trends had been observed previously for P-stereogenic H-phosphonates. See Ref. 13.
43. NMR data previously had been used in a similar manner to assign configuration at phosphorus:. Farnham W.B., Murray Jr. R.K., and Mislow K. J. Am. Chem. Soc. 92 (1970) 5809
44. Lewis R.A., Korpiun O., and Mislow K. J. Am. Chem. Soc. 90 (1968) 4847
45. Fmoc-Arg(Pbf)-OH is commercially available; pbf = 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.